FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385651488> ?p ?o ?g. }

• W4385651488 endingPage "e38888d8" @default.
• W4385651488 startingPage "e38888d8" @default.
• W4385651488 abstract "Topic: 22. Stem cell transplantation - Clinical Background: Cytomegalovirus (CMV) infection is an important cause of morbidity and mortality in allogeneic stem cell transplant recipients (ASCT). Since the introduction of prophylactic and preemptive therapies, the incidence of CMV disease has been significantly reduced. Aims: We compared the efficacy and safety of oral and intravenous anti-CMV preemptive therapy in ASCT recipients. Methods: Retrospective study including patients who received their first ASCT between January 2018 and June 2022 at the National Bone Marrow Transplant Center in Tunisia. Viral load was assessed weekly from day+15 to day+100. Monitoring of CMV infection was performed by real time PCR in EDTA plasma (Cobas AmpliPrep/ COBAS TaqMan), with 56 IU/mL as limit of detection and 137 UI/mL as limit of quantification. Reactivation was considered positive if qPCR is higher than 150 copies/mL. Response was defined by undetectable qPCR. Preemptive therapy is started if qPCR ≥150 cps/mL in patients on steroid or qPCR ≥150 cps/mL with increasing load in two consecutive tests and stopped in patients with undetectable qPCR in two consecutive tests. Anti-viral prophylaxis consisted of high dose Aciclovir given from day+1 until preemptive therapy. Results: Fifty-five patients were included developing 72 CMV reactivations. Patients’ median age was 29 years (range, 6-50). Underlying diseases were aplastic anemia (n=10), acute leukemia (n=38), myelodysplastic syndrome (n=3), chronic myeloid leukemia (n=2), lymphoma (n=1) and myelofibrosis (n=1). All patients are at high risk of CMV reactivation. Stem cell sources were bone marrow and peripheral blood stem cell in 32 (58%) and 23 (42%) patients, respectively. CMV reactivations are observed at a median of 43 days (range, 16-270) post ASCT with 58 (80%) of episodes occurring before day+100. The median viral load at diagnosis was 248 copies/mL (range, 150-4800). Thirty-six (65%) of patients had acute GVHD grade II-IV and were on steroid prior to CMV infection. The first-line preemptive treatment was oral in 51 (71%) of episodes (valganciclovir, n=40; leflunomide, n=11) and intravenous in 21 (29%) of episodes (foscarnet, n=16; ganciclovir, n= 5). All patients responded to anti-CMV therapy, 69% and 76% responded to first line therapy at a median time of 27 and 21 days with oral and intravenous therapies, respectively. Sixteen (31%) and 4 (19%) episodes needed second line therapy, in oral and intravenous group, respectively. Hematological toxicity was significantly higher in the oral group (61% vs 29%, p=0.013). Neutropenia and thrombocytopenia grad ≥2 were observed in 17(33%) vs 3 (14%) and 20 (39%) vs 2 (9%) in oral and intravenous groups, respectively. With the median follow up in the entire cohort of 18 months (range, 2-55), the 2-years overall survival (OS) and event-free survival (EFS) was 85% and 75%, respectively. Cumulative incidences of relapse and non-relapse mortality were 29% and 6%, respectively with no significant differences between oral and intravenous therapy. Summary/Conclusion: Our results showed that oral preemptive therapy for CMV reactivations after ASCT is as effective as intravenous formulations, but it is associated with more hematological toxicity. Keywords: Clinical outcome, Bone marrow transplant, CMV, Therapy" @default.
• W4385651488 created "2023-08-09" @default.
• W4385651488 creator A5026969553 @default.
• W4385651488 creator A5029194307 @default.
• W4385651488 creator A5041363302 @default.
• W4385651488 creator A5042851949 @default.
• W4385651488 creator A5053083313 @default.
• W4385651488 creator A5053643588 @default.
• W4385651488 creator A5056716451 @default.
• W4385651488 creator A5062056437 @default.
• W4385651488 creator A5077504220 @default.
• W4385651488 creator A5081538867 @default.
• W4385651488 creator A5092611184 @default.
• W4385651488 creator A5092611185 @default.
• W4385651488 creator A5092611186 @default.
• W4385651488 creator A5092611187 @default.
• W4385651488 date "2023-08-01" @default.
• W4385651488 modified "2023-09-26" @default.
• W4385651488 title "PB2424: ORAL VERSUS INTRAVENOUS ANTI-CMV PREEMPTIVE THERAPY IN ALLOGENEIC STEM CELL TRANSPLANT PATIENTS WITH CMV REACTIVATION: EXPERIENCE FROM NATIONAL CENTER OF BONE MARROW TRANSPLANTATION, TUNISIA." @default.
• W4385651488 doi "https://doi.org/10.1097/01.hs9.0000976404.38888.d8" @default.
• W4385651488 hasPublicationYear "2023" @default.
• W4385651488 type Work @default.
• W4385651488 citedByCount "0" @default.
• W4385651488 crossrefType "journal-article" @default.
• W4385651488 hasAuthorship W4385651488A5026969553 @default.
• W4385651488 hasAuthorship W4385651488A5029194307 @default.
• W4385651488 hasAuthorship W4385651488A5041363302 @default.
• W4385651488 hasAuthorship W4385651488A5042851949 @default.
• W4385651488 hasAuthorship W4385651488A5053083313 @default.
• W4385651488 hasAuthorship W4385651488A5053643588 @default.
• W4385651488 hasAuthorship W4385651488A5056716451 @default.
• W4385651488 hasAuthorship W4385651488A5062056437 @default.
• W4385651488 hasAuthorship W4385651488A5077504220 @default.
• W4385651488 hasAuthorship W4385651488A5081538867 @default.
• W4385651488 hasAuthorship W4385651488A5092611184 @default.
• W4385651488 hasAuthorship W4385651488A5092611185 @default.
• W4385651488 hasAuthorship W4385651488A5092611186 @default.
• W4385651488 hasAuthorship W4385651488A5092611187 @default.
• W4385651488 hasBestOaLocation W43856514881 @default.
• W4385651488 hasConcept C126322002 @default.
• W4385651488 hasConcept C142462285 @default.
• W4385651488 hasConcept C203014093 @default.
• W4385651488 hasConcept C2522874641 @default.
• W4385651488 hasConcept C2776409557 @default.
• W4385651488 hasConcept C2777408962 @default.
• W4385651488 hasConcept C2777600175 @default.
• W4385651488 hasConcept C2777732132 @default.
• W4385651488 hasConcept C2777965375 @default.
• W4385651488 hasConcept C2778461978 @default.
• W4385651488 hasConcept C2779820661 @default.
• W4385651488 hasConcept C2780007613 @default.
• W4385651488 hasConcept C2780727368 @default.
• W4385651488 hasConcept C2781440808 @default.
• W4385651488 hasConcept C28328180 @default.
• W4385651488 hasConcept C2911091166 @default.
• W4385651488 hasConcept C54355233 @default.
• W4385651488 hasConcept C71924100 @default.
• W4385651488 hasConcept C86803240 @default.
• W4385651488 hasConcept C90924648 @default.
• W4385651488 hasConceptScore W4385651488C126322002 @default.
• W4385651488 hasConceptScore W4385651488C142462285 @default.
• W4385651488 hasConceptScore W4385651488C203014093 @default.
• W4385651488 hasConceptScore W4385651488C2522874641 @default.
• W4385651488 hasConceptScore W4385651488C2776409557 @default.
• W4385651488 hasConceptScore W4385651488C2777408962 @default.
• W4385651488 hasConceptScore W4385651488C2777600175 @default.
• W4385651488 hasConceptScore W4385651488C2777732132 @default.
• W4385651488 hasConceptScore W4385651488C2777965375 @default.
• W4385651488 hasConceptScore W4385651488C2778461978 @default.
• W4385651488 hasConceptScore W4385651488C2779820661 @default.
• W4385651488 hasConceptScore W4385651488C2780007613 @default.
• W4385651488 hasConceptScore W4385651488C2780727368 @default.
• W4385651488 hasConceptScore W4385651488C2781440808 @default.
• W4385651488 hasConceptScore W4385651488C28328180 @default.
• W4385651488 hasConceptScore W4385651488C2911091166 @default.
• W4385651488 hasConceptScore W4385651488C54355233 @default.
• W4385651488 hasConceptScore W4385651488C71924100 @default.
• W4385651488 hasConceptScore W4385651488C86803240 @default.
• W4385651488 hasConceptScore W4385651488C90924648 @default.
• W4385651488 hasIssue "S3" @default.
• W4385651488 hasLocation W43856514881 @default.
• W4385651488 hasLocation W43856514882 @default.
• W4385651488 hasOpenAccess W4385651488 @default.
• W4385651488 hasPrimaryLocation W43856514881 @default.
• W4385651488 hasRelatedWork W1846771597 @default.
• W4385651488 hasRelatedWork W2004842203 @default.
• W4385651488 hasRelatedWork W2015037624 @default.
• W4385651488 hasRelatedWork W2027173317 @default.
• W4385651488 hasRelatedWork W2116577198 @default.
• W4385651488 hasRelatedWork W2304107253 @default.
• W4385651488 hasRelatedWork W2381711727 @default.
• W4385651488 hasRelatedWork W2790885129 @default.
• W4385651488 hasRelatedWork W2972756856 @default.
• W4385651488 hasRelatedWork W4248499721 @default.
• W4385651488 hasVolume "7" @default.
• W4385651488 isParatext "false" @default.
• W4385651488 isRetracted "false" @default.
• W4385651488 workType "article" @default.